On 8 November 2023, leading tuberculosis (TB) drug developer, UNITE4TB, of which the European Respiratory Society (ERS) is a consortium member, announced the start of its phase 2B/C clinical trial programme, with the first participant enrolled at its trial site in Cappe Town, South Africa. These trials are a major milestone for the TB community.
Find out more | Order your print copy of The Challenge of Tuberculosis in the 21st Century
Wednesday 22 November 2023
A new dawn in the fight against TB: UNITE4TB starts phase 2 clinical trials
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment